Start with non-small cell lung carcinoma, then reuse UniProt P25025 as the stable protein anchor across project notes and exports.
CHEMBL2096909 Target Snapshot
Interleukin-8 receptors, CXCR1/CXCR2 · PROTEIN FAMILY · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Interleukin-8 receptors, CXCR1/CXCR2 shows clinical signal disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P25025. Start with non-small cell lung carcinoma, then reuse UniProt P25025 as the stable protein anchor across project notes and exports.
Interleukin-8 receptors, CXCR1/CXCR2 shows clinical signal disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with non-small cell lung carcinoma because it currently carries clinical signal support. Linked drugs include SX-682. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyC-X-C chemokine receptor type 2
Review this target as Interleukin-8 receptors, CXCR1/CXCR2, mapped to UniProt P25025. ChEMBL maps the protein component as C-X-C chemokine receptor type 2. Sequence length is 360 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Interleukin-8 receptors, CXCR1/CXCR2 as ChEMBL target CHEMBL2096909, mapped to UniProt P25025. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Interleukin-8 receptors, CXCR1/CXCR2 is the right protein anchor across sources, using UniProt P25025 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why non-small cell lung carcinoma is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Interleukin-8 receptors, CXCR1/CXCR2 |
| Target Type | PROTEIN FAMILY |
| Organism | Homo sapiens |
| UniProt | P25025 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | C-X-C chemokine receptor type 2 |
| UniProt Accession | P25025 |
| Component Type | Protein |
| Sequence Length | 360 aa |
C-X-C chemokine receptor type 2
How to read this target
Review this target as Interleukin-8 receptors, CXCR1/CXCR2, mapped to UniProt P25025. ChEMBL maps the protein component as C-X-C chemokine receptor type 2. Sequence length is 360 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Interleukin-8 receptors, CXCR1/CXCR2 shows clinical signal disease relevance led by non-small cell lung carcinoma. 5 more disease programs remain visible in the same review block.
How to read disease relevance
Start review with non-small cell lung carcinoma because it currently carries clinical signal support. Linked drugs include SX-682. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL190899 | 8.74 | IC50 | 1.8 | Preclinical |
| CHEMBL191413 | 8.28 | IC50 | 5.3 | Clinical |
| CHEMBL254942 | 8.1 | IC50 | 8.0 | Preclinical |
| CHEMBL403547 | 8.1 | IC50 | 8.0 | Preclinical |
| CHEMBL254943 | 7.89 | IC50 | 13.0 | Preclinical |
| CHEMBL216981 | 7.8 | IC50 | 16.0 | Clinical |
| CHEMBL3426944 | 7.66 | IC50 | 22.0 | Preclinical |
| CHEMBL403206 | 7.57 | IC50 | 27.0 | Preclinical |
| CHEMBL253305 | 7.55 | IC50 | 28.0 | Preclinical |
| CHEMBL372052 | 7.47 | IC50 | 34.0 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Functional — 17 assays, 50 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 10 | 21 | 7.0 |
| assay format | 7 | 29 | 6.8 |
Binding — 12 assays, 33 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| protein format | 7 | 33 | 4.7 |
| cell-based format | 4 | 0 | — |
| assay format | 1 | 0 | — |